{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T14:19:23Z","timestamp":1789395563566,"version":"build-2803163510"},"publisher-location":"Berlin, Heidelberg","reference-count":181,"publisher":"Springer Berlin Heidelberg","isbn-type":[{"value":"9783642273391","type":"print"},{"value":"9783642273407","type":"electronic"}],"license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013]]},"DOI":"10.1007\/978-3-642-27340-7_12","type":"book-chapter","created":{"date-parts":[[2013,3,5]],"date-time":"2013-03-05T16:21:10Z","timestamp":1362500470000},"page":"289-320","source":"Crossref","is-referenced-by-count":9,"title":["Hepatitis C Virus-Specific Directly Acting Antiviral Drugs"],"prefix":"10.1007","author":[{"given":"Leen","family":"Delang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Neyts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge","family":"Vliegen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Abrignani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Neddermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"De Francesco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"12_CR1","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1016\/S0168-8278(07)61604-3","volume":"46","author":"N Afdhal","year":"2007","unstructured":"Afdhal N, O\u2019Brien C, Godofsky E et al (2007) Valopicitabine (NM283), alone or with peginterferon, compared to peg interferon\/ribavirin (pegIFN\/RBV) retreatment in patients with HCV-1 infection and prior non-response to pegIFN\/RBV: one-year results. J Hepatol 46:S5","journal-title":"J Hepatol"},{"key":"12_CR2","doi-asserted-by":"publisher","unstructured":"Agarwal A, Zhang B, Olek E et al (2012) Rapid and sharp decline in hepatitis C virus upon monotherapy with NS3 protease inhibitor, ACH-1625. Antivirus Therapy, in press. doi:10.3851\/IMP2359","DOI":"10.3851\/IMP2359"},{"key":"12_CR3","doi-asserted-by":"publisher","unstructured":"Aghemo A, Degasperi E, Colombo M (2012) Directly acting antivirals for the treatment of chronic hepatitis C: unresolved topics from registration trials. Digistive and liver disease, in press. doi:10.1016\/j.dld.2012.05.002","DOI":"10.1016\/j.dld.2012.05.002"},{"key":"12_CR4","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/clpt.2012.103","volume":"92","author":"DN Assis","year":"2012","unstructured":"Assis DN, Lim JK (2012) New pharmacotherapy for hepatitis C. Clin Pharmacol Ther 92:294\u2013305","journal-title":"Clin Pharmacol Ther"},{"key":"12_CR5","first-page":"39","volume":"9","author":"PL Beaulieu","year":"2006","unstructured":"Beaulieu PL (2006) The discovery of finger loop inhibitors of the hepatitis C virus NS5B polymerase: status and prospects for novel HCV therapeutics. IDrugs 9:39\u201343","journal-title":"IDrugs"},{"key":"12_CR6","doi-asserted-by":"publisher","first-page":"7650","DOI":"10.1021\/jm3006788","volume":"55","author":"PL Beaulieu","year":"2012","unstructured":"Beaulieu PL, Bos M, Cordingley MG et al (2012) Discovery of the first thumb pocket 1 NS5B polymerase inhibitor (BILB 1941) with demonstrated antiviral activity in patients chronically infected with genotype 1 hepatitis C virus (HCV). J Med Chem 55:7650\u20137666","journal-title":"J Med Chem"},{"key":"12_CR7","doi-asserted-by":"publisher","unstructured":"Belda O, Targett-Adams P (2012) Small molecule inhibitors of the hepatitis C virus-encoded NS5A protein. Virus Research, in press. doi:10.1016\/j.virusres.2012.09.007","DOI":"10.1016\/j.virusres.2012.09.007"},{"issue":"1","key":"12_CR8","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.1016\/S0168-8278(09)60012-X","volume":"50","author":"Y Benhamou","year":"2009","unstructured":"Benhamou Y, Moussalli J, Ratziu V et al (2009) Results of a proof-of-concept study (C210) of telaprevir monotherapy and in combination with peginterfern alfa-2a and ribavirin in treatment-naive genotype 4 HCV patients. J Hepatol 50(1):S6","journal-title":"J Hepatol"},{"key":"12_CR9","unstructured":"Berger C, Romero-Brey I, Zayas M et al (2012) HCV NS5A inhibitors alter membranous web formation and reduce PI4P induction in cells expressing HCV non-structural proteins. In: Abstracts O23 of the 19th international symposium on hepatitis C virus and related viruses, Venice, Italy, 5\u20139 Octo 2012"},{"key":"12_CR10","doi-asserted-by":"publisher","first-page":"3812","DOI":"10.1128\/AAC.00214-11","volume":"55","author":"JM Berke","year":"2011","unstructured":"Berke JM, Vijgen L, Lachau-Durand S et al (2011) Antiviral activity and mode of action of TMC647078, a novel nucleoside inhibitor of the hepatitis C virus NS5B polymerase. Antimicrob Agents Chemother 55:3812\u20133820","journal-title":"Antimicrob Agents Chemother"},{"key":"12_CR11","first-page":"1026A","volume":"50","author":"DM Brainard","year":"2009","unstructured":"Brainard DM, Anderson MS, Petry A et al (2009) Safety and antiviral activity of NS5B polymerase inhibitor MK-3281, in treatment-na\u00efve genotype 1a, 1b and 3 HCV-infected patients. Hepatology 50:1026A\u20131027A","journal-title":"Hepatology"},{"issue":"1","key":"12_CR12","first-page":"706A","volume":"52","author":"DM Brainard","year":"2010","unstructured":"Brainard DM, Petry A, Van Dyck K et al (2010) Safety and antiviral activity of MK-5172, a novel HCV NS3\/4A protease inhibitor with potent activity against known resistance mutants in genotype 1 and 3 HCV-infected patients. Hepatology 52(1):706A\u2013707A","journal-title":"Hepatology"},{"key":"12_CR13","doi-asserted-by":"publisher","first-page":"13034","DOI":"10.1073\/pnas.96.23.13034","volume":"96","author":"S Bressanelli","year":"1999","unstructured":"Bressanelli S, Tomei L, Roussel A et al (1999) Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Proc Natl Acad Sci USA 96:13034\u201313039","journal-title":"Proc Natl Acad Sci USA"},{"key":"12_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.antiviral.2010.03.013","volume":"87","author":"PD Bryson","year":"2010","unstructured":"Bryson PD, Cho NJ, Einav S et al (2010) A small molecule inhibits HCV replication and alters NS4B\u2019s subcellular distribution. Antiviral Res 87:1\u20138","journal-title":"Antiviral Res"},{"key":"12_CR15","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1128\/JVI.76.8.3720-3730.2002","volume":"76","author":"S Carrere-Kremer","year":"2002","unstructured":"Carrere-Kremer S, Montpellier-Pala C, Cocquerel L et al (2002) Subcellular localization and topology of the p7 polypeptide of hepatitis C virus. J Virol 76:3720\u20133730","journal-title":"J Virol"},{"key":"12_CR16","doi-asserted-by":"publisher","first-page":"17","DOI":"10.2174\/187152606776056698","volume":"6","author":"SS Carroll","year":"2006","unstructured":"Carroll SS, Olsen DB (2006) Nucleoside analog inhibitors of hepatitis C virus replication. Infect Disord Drug Targets 6:17\u201329","journal-title":"Infect Disord Drug Targets"},{"key":"12_CR17","doi-asserted-by":"publisher","first-page":"11979","DOI":"10.1074\/jbc.M210914200","volume":"278","author":"SS Carroll","year":"2003","unstructured":"Carroll SS, Tomassini JE, Bosserman M et al (2003) Inhibition of hepatitis C virus RNA replication by 2\u2032-modified nucleoside analogs. J Biol Chem 278:11979\u201311984","journal-title":"J Biol Chem"},{"key":"12_CR18","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1016\/j.clinthera.2012.08.009","volume":"34","author":"MH Chang","year":"2012","unstructured":"Chang MH, Gordon LA, Fung HB (2012) Boceprevir: a protease inhibitor for the treatment of hepatitis C. Clin Ther 34:2021\u20132038","journal-title":"Clin Ther"},{"key":"12_CR19","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.coviro.2012.08.002","volume":"2","author":"L Chatel-Chaix","year":"2012","unstructured":"Chatel-Chaix L, Germain MA, Gotte M, Lamarre D (2012) Direct-acting and host-targeting HCV inhibitors: current and future directions. Curr Opin Virol 2:588\u2013598","journal-title":"Curr Opin Virol"},{"key":"12_CR20","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.2174\/0929867054864769","volume":"12","author":"SH Chen","year":"2005","unstructured":"Chen SH, Tan SL (2005) Discovery of small-molecule inhibitors of HCV NS3-4A protease as potential therapeutic agents against HCV infection. Curr Med Chem 12:2317\u20132342","journal-title":"Curr Med Chem"},{"key":"12_CR21","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1126\/scitranslmed.3000331","volume":"2","author":"NJ Cho","year":"2010","unstructured":"Cho NJ, Dvory-Sobol H, Lee C et al (2010) Identification of a class of HCV inhibitors directed against the nonstructural protein NS4B. Sci Transl Med 2:15\u201316","journal-title":"Sci Transl Med"},{"key":"12_CR22","unstructured":"Choong IC, Cory D, Glenn JS, Yang W (2010) Methods and compositions of treating a Flaviviridae family viral infection. WO\/2010\/107739"},{"key":"12_CR23","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1016\/j.bmcl.2009.01.066","volume":"19","author":"I Conte","year":"2009","unstructured":"Conte I, Giuliano C, Ercolani C et al (2009) Synthesis and SAR of piperazinyl-N-phenylbenzamides as inhibitors of hepatitis C virus RNA replication in cell culture. Bioorg Med Chem Lett 19:1779\u20131783","journal-title":"Bioorg Med Chem Lett"},{"key":"12_CR24","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jhep.2009.03.015","volume":"51","author":"C Cooper","year":"2009","unstructured":"Cooper C, Lawitz EJ, Ghali P et al (2009) Evaluation of VCH-759 monotherapy in hepatitis C infection. J Hepatol 51:39\u201346","journal-title":"J Hepatol"},{"key":"12_CR25","first-page":"149","volume":"242","author":"R De Francesco","year":"2000","unstructured":"De Francesco R, Steinkuhler C (2000) Structure and function of the hepatitis C virus NS3-NS4A serine proteinase. Curr Top Microbiol Immunol 242:149\u2013169","journal-title":"Curr Top Microbiol Immunol"},{"key":"12_CR26","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.antiviral.2011.10.012","volume":"93","author":"L Delang","year":"2012","unstructured":"Delang L, Froeyen M, Herdewijn P, Neyts J (2012) Identification of a novel resistance mutation for benzimidazole inhibitors of the HCV RNA-dependent RNA polymerase. Antiviral Res 93:30\u201338","journal-title":"Antiviral Res"},{"key":"12_CR27","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.jhep.2004.05.019","volume":"41","author":"P Deltenre","year":"2004","unstructured":"Deltenre P, Henrion J, Canva V et al (2004) Evaluation of amantadine in chronic hepatitis C: a meta-analysis. J Hepatol 41:462\u2013473","journal-title":"J Hepatol"},{"key":"12_CR28","doi-asserted-by":"publisher","first-page":"4676","DOI":"10.1128\/AAC.00245-12","volume":"56","author":"B Devogelaere","year":"2012","unstructured":"Devogelaere B, Berke JM, Vijgen L et al (2012) TMC647055, a potent nonnucleoside hepatitis C virus NS5B polymerase inhibitor with cross-genotypic coverage. Antimicrob Agents Chemother 56:4676\u20134684","journal-title":"Antimicrob Agents Chemother"},{"key":"12_CR29","doi-asserted-by":"publisher","first-page":"29765","DOI":"10.1074\/jbc.M505423200","volume":"280","author":"S Di Marco","year":"2005","unstructured":"Di Marco S, Volpari C, Tomei L et al (2005) Interdomain communication in hepatitis C virus polymerase abolished by small molecule inhibitors bound to a novel allosteric site. J Biol Chem 280:29765\u201329770","journal-title":"J Biol Chem"},{"key":"12_CR30","doi-asserted-by":"publisher","first-page":"5289","DOI":"10.1128\/AAC.00780-12","volume":"56","author":"H Dvory-Sobol","year":"2012","unstructured":"Dvory-Sobol H, Wong KA, Ku KS et al (2012) Characterization of resistance to the protease inhibitor GS-9451 in hepatitis C virus-infected patients. Antimicrob Agents Chemother 56:5289\u20135295","journal-title":"Antimicrob Agents Chemother"},{"key":"12_CR31","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/med.2610140202","volume":"14","author":"PD Edwards","year":"1994","unstructured":"Edwards PD, Bernstein PR (1994) Synthetic inhibitors of elastase. Med Res Rev 14:127\u2013194","journal-title":"Med Res Rev"},{"key":"12_CR32","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1038\/nbt.1490","volume":"26","author":"S Einav","year":"2008","unstructured":"Einav S, Gerber D, Bryson PD et al (2008) Discovery of a hepatitis C target and its pharmacological inhibitors by microfluidic affinity analysis. Nat Biotechnol 26:1019\u20131027","journal-title":"Nat Biotechnol"},{"key":"12_CR33","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1086\/653080","volume":"202","author":"S Einav","year":"2010","unstructured":"Einav S, Sobol HD, Gehrig E, Glenn JS (2010) The hepatitis C virus (HCV) NS4B RNA binding inhibitor clemizole is highly synergistic with HCV protease inhibitors. J Infect Dis 202:65\u201374","journal-title":"J Infect Dis"},{"key":"12_CR34","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1099\/vir.0.19305-0","volume":"84","author":"N El Hage","year":"2003","unstructured":"El Hage N, Luo G (2003) Replication of hepatitis C virus RNA occurs in a membrane-bound replication complex containing nonstructural viral proteins and RNA. J Gen Virol 84:2761\u20132769","journal-title":"J Gen Virol"},{"key":"12_CR35","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1177\/135965350901400104","volume":"14","author":"A Erhardt","year":"2009","unstructured":"Erhardt A, Deterding K, Benhamou Y et al (2009) Safety, pharmacokinetics and antiviral effect of BILB 1941, a novel hepatitis C virus RNA polymerase inhibitor, after 5\u00a0days oral treatment. Antiviral Ther 14:23\u201332","journal-title":"Antiviral Ther"},{"key":"#cr-split#-12_CR36.1","unstructured":"Everson GT, Sims KD, Rodriguez-Torres M et al (2012) An interferon-free, ribavirin-free 12\u00a0weeks regimen of daclatasvir (DCV), asunaprevir (ASV), and BMS-791325 yielded SVR4 of 94\u00a0% in treatment-na\u00efve patients with genotype"},{"key":"#cr-split#-12_CR36.2","unstructured":"(GT) 1 chronic hepatitis C virus (HCV) infection. In: Abstracts LB-3 of the 63rd annual meeting of the american association for the study of liver diseases, Boston, Massachusetts, 9-13 Nov 2012"},{"key":"12_CR37","doi-asserted-by":"publisher","first-page":"3753","DOI":"10.1128\/jvi.68.6.3753-3760.1994","volume":"68","author":"C Failla","year":"1994","unstructured":"Failla C, Tomei L, De Francesco R (1994) Both NS3 and NS4A are required for proteolytic processing of hepatitis C virus nonstructural proteins. J Virol 68:3753\u20133760","journal-title":"J Virol"},{"key":"12_CR38","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1128\/jvi.69.3.1769-1777.1995","volume":"69","author":"C Failla","year":"1995","unstructured":"Failla C, Tomei L, De Francesco R (1995) An amino-terminal domain of the hepatitis C virus NS3 protease is essential for interaction with NS4A. J Virol 69:1769\u20131777","journal-title":"J Virol"},{"issue":"1","key":"12_CR39","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/j.1478-3231.2011.02705.x","volume":"32","author":"P Ferenci","year":"2012","unstructured":"Ferenci P (2012) Treatment of chronic hepatitis C: are interferons really necessary? Liver Int 32(1):108\u2013112","journal-title":"Liver Int"},{"key":"12_CR40","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1517\/14656566.2012.660524","volume":"13","author":"N Forestier","year":"2012","unstructured":"Forestier N, Zeuzem S (2012) Telaprevir for the treatment of hepatitis C. Expert Opin Pharmacother 13:593\u2013606","journal-title":"Expert Opin Pharmacother"},{"key":"12_CR41","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1016\/j.jhep.2010.11.001","volume":"54","author":"N Forestier","year":"2011","unstructured":"Forestier N, Larrey D, Guyader D et al (2011) Treatment of chronic hepatitis C patients with the NS3\/4A protease inhibitor danoprevir (ITMN-191\/RG7227) leads to robust reductions in viral RNA: a phase 1b multiple ascending dose study. J Hepatol 54:1130\u20131136","journal-title":"J Hepatol"},{"issue":"881\u2013889","key":"12_CR42","doi-asserted-by":"publisher","first-page":"e881","DOI":"10.1053\/j.gastro.2011.05.046","volume":"141","author":"GR Foster","year":"2011","unstructured":"Foster GR, Hezode C, Bronowicki JP et al (2011a) Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections. Gastroenterology 141(881\u2013889):e881","journal-title":"Gastroenterology"},{"key":"12_CR43","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/hep.24371","volume":"54","author":"TL Foster","year":"2011","unstructured":"Foster TL, Verow M, Wozniak AL et al (2011b) Resistance mutations define specific antiviral effects for inhibitors of the hepatitis C virus p7 ion channel. Hepatology 54:79\u201390","journal-title":"Hepatology"},{"key":"12_CR44","doi-asserted-by":"publisher","first-page":"3641","DOI":"10.1128\/AAC.00556-10","volume":"54","author":"RA Fridell","year":"2010","unstructured":"Fridell RA, Qiu D, Wang C et al (2010) Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system. Antimicrob Agents Chemother 54:3641\u20133650","journal-title":"Antimicrob Agents Chemother"},{"key":"12_CR45","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1002\/hep.24594","volume":"54","author":"RA Fridell","year":"2011","unstructured":"Fridell RA, Wang C, Sun JH et al (2011) Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations. Hepatology 54:1924\u20131935","journal-title":"Hepatology"},{"key":"12_CR46","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1016\/S0140-6736(10)61384-0","volume":"376","author":"EJ Gane","year":"2010","unstructured":"Gane EJ, Roberts SK, Stedman CAM et al (2010) Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 376:1467\u20131475","journal-title":"Lancet"},{"key":"12_CR47","unstructured":"Gane E, Stedman C, Hyland RH et al (2012a) Once daily sofosbuvir (GS-7977) plus ribavirin in patients with HCV genotypes 1, 2, and 3: the electron trial. In: Abstracts 229 of the 63rd annual meeting of the american association for the study of liver diseases, Boston, Massachusetts, 9\u201313 Nov 2012"},{"issue":"2","key":"12_CR48","doi-asserted-by":"publisher","first-page":"S438","DOI":"10.1016\/S0168-8278(12)61125-8","volume":"56","author":"EJ Gane","year":"2012","unstructured":"Gane EJ, Stedman CA, Hyland RH et al (2012b) Electron: once daily PSI-7977 plus RBV in HCV GT1\/2\/3. J Hepatol 56(2):S438\u2013S439","journal-title":"J Hepatol"},{"key":"12_CR49","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/nature08960","volume":"465","author":"M Gao","year":"2010","unstructured":"Gao M, Nettles RE, Belema M et al (2010) Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 465:96\u2013100","journal-title":"Nature"},{"key":"12_CR50","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.bmcl.2005.08.114","volume":"16","author":"A Gopalsamy","year":"2006","unstructured":"Gopalsamy A, Aplasca A, Ciszewski G et al (2006) Design and synthesis of 3,4-dihydro-1H-[1]-benzothieno[2,3-c]pyran and 3,4-dihydro-1H-pyrano[3,4-b]benzofuran derivatives as non-nucleoside inhibitors of HCV NS5B RNA dependent RNA polymerase. Bioorg Med Chem Lett 16:457\u2013460","journal-title":"Bioorg Med Chem Lett"},{"key":"12_CR51","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1517\/13543784.14.9.1129","volume":"14","author":"N Goudreau","year":"2005","unstructured":"Goudreau N, Llinas-Brunet M (2005) The therapeutic potential of NS3 protease inhibitors in HCV infection. Expert Opin Investig Drugs 14:1129\u20131144","journal-title":"Expert Opin Investig Drugs"},{"key":"12_CR52","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1002\/rmv.640","volume":"20","author":"J Gouttenoire","year":"2010","unstructured":"Gouttenoire J, Penin F, Moradpour D (2010) Hepatitis C virus nonstructural protein 4B: a journey into unexplored territory. Rev Med Virol 20:117\u2013129","journal-title":"Rev Med Virol"},{"key":"12_CR53","doi-asserted-by":"publisher","first-page":"S225","DOI":"10.1016\/S0168-8278(07)62192-8","volume":"46","author":"F Gray","year":"2007","unstructured":"Gray F, Amphlett E, Bright H et al (2007) GSK625433; a novel and highly potent inhibitor of the HCVNS5B polymerase. J Hepatol 46:S225","journal-title":"J Hepatol"},{"key":"12_CR54","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/S0014-5793(02)03851-6","volume":"535","author":"SD Griffin","year":"2003","unstructured":"Griffin SD, Beales LP, Clarke DS et al (2003) The p7 protein of hepatitis C virus forms an ion channel that is blocked by the antiviral drug, amantadine. FEBS Lett 535:34\u201338","journal-title":"FEBS Lett"},{"key":"12_CR55","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1002\/hep.22555","volume":"48","author":"S Griffin","year":"2008","unstructured":"Griffin S, StGelais C, Owsianka AM et al (2008) Genotype-dependent sensitivity of hepatitis C virus to inhibitors of the p7 ion channel. Hepatology 48:1779\u20131790","journal-title":"Hepatology"},{"key":"12_CR56","doi-asserted-by":"publisher","first-page":"16602","DOI":"10.1074\/jbc.M210891200","volume":"278","author":"B Gu","year":"2003","unstructured":"Gu B, Johnston VK, Gutshall LL et al (2003) Arresting initiation of hepatitis C virus RNA synthesis using heterocyclic derivatives. J Biol Chem 278:16602\u201316607","journal-title":"J Biol Chem"},{"key":"12_CR57","doi-asserted-by":"publisher","first-page":"e39163","DOI":"10.1371\/journal.pone.0039163","volume":"7","author":"CM Hebner","year":"2012","unstructured":"Hebner CM, Han B, Brendza KM et al (2012) The HCV Non-nucleoside inhibitor tegobuvir utilizes a novel mechanism of action to inhibit NS5B polymerase function. Plos One 7:e39163","journal-title":"Plos One"},{"key":"12_CR58","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1006\/viro.2001.0948","volume":"285","author":"Z Hong","year":"2001","unstructured":"Hong Z, Cameron CE, Walker MP et al (2001) A novel mechanism to ensure terminal initiation by hepatitis C virus NS5B polymerase. Virology 285:6\u201311","journal-title":"Virology"},{"key":"12_CR59","doi-asserted-by":"publisher","first-page":"4813","DOI":"10.1128\/AAC.48.12.4813-4821.2004","volume":"48","author":"AY Howe","year":"2004","unstructured":"Howe AY, Bloom J, Baldick CJ et al (2004) Novel nonnucleoside inhibitor of hepatitis C virus RNA-dependent RNA polymerase. Antimicrob Agents Chemother 48:4813\u20134821","journal-title":"Antimicrob Agents Chemother"},{"key":"12_CR60","doi-asserted-by":"publisher","first-page":"4103","DOI":"10.1128\/AAC.00365-06","volume":"50","author":"AY Howe","year":"2006","unstructured":"Howe AY, Cheng H, Thompson I et al (2006) Molecular mechanism of a thumb domain hepatitis C virus nonnucleoside RNA-dependent RNA polymerase inhibitor. Antimicrob Agents Chemother 50:4103\u20134113","journal-title":"Antimicrob Agents Chemother"},{"key":"12_CR61","doi-asserted-by":"publisher","first-page":"3327","DOI":"10.1128\/AAC.00238-08","volume":"52","author":"AY Howe","year":"2008","unstructured":"Howe AY, Cheng H, Johann S et al (2008) Molecular mechanism of hepatitis C virus replicon variants with reduced susceptibility to a benzofuran inhibitor, HCV-796. Antimicrob Agents Chemother 52:3327\u20133338","journal-title":"Antimicrob Agents Chemother"},{"key":"12_CR62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.virol.2007.01.042","volume":"364","author":"Y Huang","year":"2007","unstructured":"Huang Y, Staschke K, De Francesco R, Tan SL (2007) Phosphorylation of hepatitis C virus NS5A nonstructural protein: a new paradigm for phosphorylation-dependent viral RNA replication? Virology 364:1\u20139","journal-title":"Virology"},{"issue":"S1","key":"12_CR63","first-page":"1204A","volume":"52","author":"M Huang","year":"2010","unstructured":"Huang M, Podos S, Patel D et al (2010) ACH-2684: HCV NS3 protease inhibitor with potent activity against multiple genotypes and known resistant variants. Hepatology 52(S1):1204A","journal-title":"Hepatology"},{"key":"12_CR64","doi-asserted-by":"publisher","first-page":"S382","DOI":"10.1016\/S0168-8278(09)61054-0","volume":"50","author":"I Jacobson","year":"2009","unstructured":"Jacobson I, Pockros P, Lalezari J et al (2009) Antiviral activity of filibuvir in combination with pegylated interferon alfa-2a and ribavirin for 28\u00a0days in treatment naive patients chronically infected with HCV genotype 1. J Hepatol 50:S382\u2013S383","journal-title":"J Hepatol"},{"key":"12_CR65","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1021\/jm201278q","volume":"55","author":"WM Kazmierski","year":"2012","unstructured":"Kazmierski WM, Hamatake R, Duan M et al (2012) Discovery of novel urea-based hepatitis C protease inhibitors with high potency against protease-inhibitor-resistant mutants. J Med Chem 55:3021\u20133026","journal-title":"J Med Chem"},{"key":"12_CR66","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1128\/AAC.01308-09","volume":"54","author":"G Khoury","year":"2010","unstructured":"Khoury G, Ewart G, Luscombe C et al (2010) Antiviral efficacy of the novel compound BIT225 against HIV-1 release from human macrophages. Antimicrob Agents Chemother 54:835\u2013845","journal-title":"Antimicrob Agents Chemother"},{"key":"12_CR67","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1002\/hep.21781","volume":"46","author":"TL Kieffer","year":"2007","unstructured":"Kieffer TL, Sarrazin C, Miller JS et al (2007) Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology 46:631\u2013639","journal-title":"Hepatology"},{"key":"12_CR68","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/S0092-8674(00)81351-3","volume":"87","author":"JL Kim","year":"1996","unstructured":"Kim JL, Morgenstern KA, Lin C et al (1996) Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell 87:343\u2013355","journal-title":"Cell"},{"key":"12_CR69","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1002\/hep.22717","volume":"49","author":"NM Kneteman","year":"2009","unstructured":"Kneteman NM, Howe AYM, Gao TJ et al (2009) HCV796: a selective nonstructural protein 5B polymerase inhibitor with potent anti-hepatitis C virus activity in vitro, in mice with chimeric human livers, and in humans infected with hepatitis C virus. Hepatology 49:745\u2013752","journal-title":"Hepatology"},{"issue":"2","key":"12_CR70","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/S0168-8278(12)00243-7","volume":"56","author":"KV Kowdley","year":"2012","unstructured":"Kowdley KV, Lawitz E, Crespo I et al (2012a) Atomic: 97\u00a0% RVR for PSI-7977\u00a0+\u00a0PEG\/RBV X 12\u00a0weeks regimen in HCV GT1: an end to response-guided therapy? J Hepatol 56(2):S1","journal-title":"J Hepatol"},{"key":"12_CR71","unstructured":"Kowdley KV, Lawitz E, Poordad F et al (2012b) A 12\u00a0weeks interferon-free treatment regimen with ABT-450\/r, ABT-267, ABT-333 and ribavirin achieves SVR12 rates (observed data) of 99\u00a0% in treatment-na\u00efve patients and 93\u00a0% in prior null responders with HCV genotype1 infection. In: Abstracts LB-1 of the 63rd annual meeting of the american association for the study of liver diseases, Boston, Massachusetts, 9\u201313 Nov 2012"},{"key":"12_CR72","doi-asserted-by":"publisher","first-page":"39260","DOI":"10.1074\/jbc.M506407200","volume":"280","author":"G Kukolj","year":"2005","unstructured":"Kukolj G, McGibbon GA, McKercher G et al (2005) Binding site characterization and resistance to a class of non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase. J Biol Chem 280:39260\u201339267","journal-title":"J Biol Chem"},{"key":"12_CR73","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/S0140-6736(10)60934-8","volume":"376","author":"PY Kwo","year":"2010","unstructured":"Kwo PY, Lawitz EJ, McCone J et al (2010) Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 376:705\u2013716","journal-title":"Lancet"},{"key":"12_CR74","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1128\/AAC.05166-11","volume":"56","author":"L Lagace","year":"2012","unstructured":"Lagace L, White PW, Bousquet C et al (2012) In vitro resistance profile of the hepatitis C virus NS3 protease inhibitor BI 201335. Antimicrob Agents Chemother 56:569\u2013572","journal-title":"Antimicrob Agents Chemother"},{"key":"12_CR75","doi-asserted-by":"publisher","first-page":"12334","DOI":"10.1128\/JVI.05639-11","volume":"85","author":"AM Lam","year":"2011","unstructured":"Lam AM, Espiritu C, Bansal S et al (2011a) Hepatitis C virus nucleotide inhibitors PSI-352938 and PSI-353661 exhibit a novel mechanism of resistance requiring multiple mutations within replicon RNA. J Virol 85:12334\u201312342","journal-title":"J Virol"},{"key":"12_CR76","doi-asserted-by":"publisher","first-page":"2566","DOI":"10.1128\/AAC.00032-11","volume":"55","author":"AM Lam","year":"2011","unstructured":"Lam AM, Espiritu C, Murakami E et al (2011b) Inhibition of hepatitis C virus replicon RNA synthesis by PSI-352938, a cyclic phosphate prodrug of {beta}-D-2\u2032-deoxy-2\u2032-{alpha}-fluoro-2\u2032-{beta}-C-Methylguanosine. Antimicrob Agents Chemother 55:2566\u20132575","journal-title":"Antimicrob Agents Chemother"},{"key":"12_CR77","doi-asserted-by":"publisher","first-page":"3359","DOI":"10.1128\/AAC.00054-12","volume":"56","author":"AM Lam","year":"2012","unstructured":"Lam AM, Espiritu C, Bansal S et al (2012) Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus. Antimicrob Agents Chemother 56:3359\u20133368","journal-title":"Antimicrob Agents Chemother"},{"key":"12_CR78","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/nature02099","volume":"426","author":"D Lamarre","year":"2003","unstructured":"Lamarre D, Anderson PC, Bailey M et al (2003) An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 426:186\u2013189","journal-title":"Nature"},{"key":"12_CR79","first-page":"1044A","volume":"50","author":"DG Larrey","year":"2009","unstructured":"Larrey DG, Benhamou Y, Lohse AW et al (2009) Bi 207127 is a potent HCV RNA polymerase inhibitor during 5\u00a0days monotherapy in patients with chronic hepatitis C. Hepatology 50:1044A","journal-title":"Hepatology"},{"key":"12_CR80","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jhep.2012.02.015","volume":"57","author":"D Larrey","year":"2012","unstructured":"Larrey D, Lohse AW, de Ledinghen V et al (2012) Rapid and strong antiviral activity of the non-nucleosidic NS5B polymerase inhibitor BI 207127 in combination with peginterferon alfa 2a and ribavirin. J Hepatol 57:39\u201346","journal-title":"J Hepatol"},{"key":"12_CR81","first-page":"223A","volume":"44","author":"E Lawitz","year":"2006","unstructured":"Lawitz E, Nguyen T, Younes Z et al (2006) Valopicitabine (NM283) plus PEG-interferon in treatment-naive hepatitis C patients with HCV genotype-1 infection: HCV RNA clearance during 24\u00a0weeks of treatment. Hepatology 44:223A","journal-title":"Hepatology"},{"key":"12_CR82","doi-asserted-by":"publisher","first-page":"S384","DOI":"10.1016\/S0168-8278(09)61057-6","volume":"50","author":"E Lawitz","year":"2009","unstructured":"Lawitz E, Rodriguez-Torres M, DeMico M et al (2009) Antiviral activity of ANA598, a potent non-nucleoside polymerase inhibitor, in chronic hepatitis C patients. J Hepatol 50:S384","journal-title":"J Hepatol"},{"issue":"1","key":"12_CR83","first-page":"878A","volume":"52","author":"E Lawitz","year":"2010","unstructured":"Lawitz E, Gaultier I, Poordad F et al (2010a) 4\u00a0weeks virologic response and safety of ABT-450 given with low-dose ritonavir (ABT-450r) in combination with pegylated interferon alfa 2a and ribavirin after 3\u00a0days monotherapy in HCV-infected treatment-naive subjects. Hepatology 52(1):878A\u2013979A","journal-title":"Hepatology"},{"key":"12_CR84","first-page":"334A","volume":"52","author":"E Lawitz","year":"2010","unstructured":"Lawitz E, Rodriguez-Torres M, Rustgi V et al (2010b) Safety and antiviral activity of ANA598 in combination with pegylated IFN alpha 2a plus ribavirin in treatment-na\u00efve genotype-1 chronic HCV patients. Hepatology 52:334A\u2013335A","journal-title":"Hepatology"},{"key":"12_CR85","doi-asserted-by":"publisher","first-page":"S543","DOI":"10.1016\/S0168-8278(11)61372-X","volume":"54","author":"E Lawitz","year":"2011","unstructured":"Lawitz E, Rodriguez-Torres M, Denning JM et al (2011) Once dialy dual-nucleotide combination of PSI-938 and PSI-7977 provides 94\u00a0% HCV RNA\u00a0<\u00a0LOD at day 14: first purine\/pyrimidine clinical combination data (the nuclear study). J Hepatol 54:S543","journal-title":"J Hepatol"},{"key":"12_CR86","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.jhep.2011.12.029","volume":"57","author":"EJ Lawitz","year":"2012","unstructured":"Lawitz EJ, Gruener D, Hill JM et al (2012) A phase 1, randomized, placebo-controlled, 3\u00a0days, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C. J Hepatol 57:24\u201331","journal-title":"J Hepatol"},{"key":"12_CR87","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.virol.2006.03.045","volume":"351","author":"S Le Pogam","year":"2006","unstructured":"Le Pogam S, Jiang WR, Leveque V et al (2006a) In vitro selected Con1 subgenomic replicons resistant to 2\u2032-C-methyl-cytidine or to R1479 show lack of cross resistance. Virology 351:349\u2013359","journal-title":"Virology"},{"key":"12_CR88","doi-asserted-by":"publisher","first-page":"6146","DOI":"10.1128\/JVI.02628-05","volume":"80","author":"S Le Pogam","year":"2006","unstructured":"Le Pogam S, Kang H, Harris SF et al (2006b) Selection and characterization of replicon variants dually resistant to thumb- and palm-binding nonnucleoside polymerase inhibitors of the hepatitis C virus. J Virol 80:6146\u20136154","journal-title":"J Virol"},{"key":"12_CR89","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1086\/656774","volume":"202","author":"S Le Pogam","year":"2010","unstructured":"Le Pogam S, Seshaadri A, Ewing A et al (2010) RG7128 alone or in combination with pegylated interferon-alpha 2a and ribavirin prevents hepatitis C virus (HCV) replication and selection of resistant variants in HCV-infected patients. J Infect Dis 202:1510\u20131519","journal-title":"J Infect Dis"},{"key":"12_CR90","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1111\/j.1742-1241.2012.02895.x","volume":"66","author":"LY Lee","year":"2012","unstructured":"Lee LY, Tong CY, Wong T, Wilkinson M (2012) New therapies for chronic hepatitis C infection: a systematic review of evidence from clinical trials. Int J Clin Pract 66:342\u2013355","journal-title":"Int J Clin Pract"},{"key":"12_CR91","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1128\/JVI.01360-09","volume":"84","author":"JA Lemm","year":"2010","unstructured":"Lemm JA, O\u2019Boyle D 2nd, Liu M et al (2010) Identification of hepatitis C virus NS5A inhibitors. J Virol 84:482\u2013491","journal-title":"J Virol"},{"key":"12_CR92","doi-asserted-by":"publisher","first-page":"3795","DOI":"10.1128\/AAC.00146-11","volume":"55","author":"JA Lemm","year":"2011","unstructured":"Lemm JA, Leet JE, O\u2019Boyle DR 2nd et al (2011) Discovery of potent hepatitis C virus NS5A inhibitors with dimeric structures. Antimicrob Agents Chemother 55:3795\u20133802","journal-title":"Antimicrob Agents Chemother"},{"key":"12_CR93","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1128\/AAC.01452-09","volume":"54","author":"O Lenz","year":"2010","unstructured":"Lenz O, Verbinnen T, Lin TI et al (2010) In vitro resistance profile of the hepatitis C virus NS3\/4A protease inhibitor TMC435. Antimicrob Agents Chemother 54:1878\u20131887","journal-title":"Antimicrob Agents Chemother"},{"key":"12_CR94","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1038\/13305","volume":"6","author":"CA Lesburg","year":"1999","unstructured":"Lesburg CA, Cable MB, Ferrari E et al (1999) Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site. Nat Struct Biol 6:937\u2013943","journal-title":"Nat Struct Biol"},{"key":"12_CR95","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1021\/jm8014537","volume":"52","author":"H Li","year":"2009","unstructured":"Li H, Tatlock J, Linton A et al (2009) Discovery of (R)-6-Cyclopentyl-6-(2-(2,6-diethylpyridin-4-yl)ethyl)-3-((5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl)-4-hydroxy-5,6-dihydropyran-2-on e (PF-00868554) as a potent and orally available hepatitis C virus polymerase inhibitor. J Med Chem 52:1255\u20131258","journal-title":"J Med Chem"},{"key":"12_CR96","doi-asserted-by":"publisher","first-page":"4373","DOI":"10.1128\/jvi.69.7.4373-4380.1995","volume":"69","author":"C Lin","year":"1995","unstructured":"Lin C, Thomson JA, Rice CM (1995) A central region in the hepatitis C virus NS4A protein allows formation of an active NS3-NS4A serine proteinase complex in vivo and in vitro. J Virol 69:4373\u20134380","journal-title":"J Virol"},{"key":"12_CR97","doi-asserted-by":"publisher","first-page":"17508","DOI":"10.1074\/jbc.M313020200","volume":"279","author":"C Lin","year":"2004","unstructured":"Lin C, Lin K, Luong YP et al (2004) In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms. J Biol Chem 279:17508\u201317514","journal-title":"J Biol Chem"},{"key":"12_CR98","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2174\/187152606776056706","volume":"6","author":"C Lin","year":"2006","unstructured":"Lin C, Kwong AD, Perni RB (2006) Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3-4A serine protease. Infect Disord Drug Targets 6:3\u201316","journal-title":"Infect Disord Drug Targets"},{"key":"12_CR99","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1128\/AAC.01058-08","volume":"53","author":"TI Lin","year":"2009","unstructured":"Lin TI, Lenz O, Fanning G et al (2009) In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor. Antimicrob Agents Chemother 53:1377\u20131385","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"12_CR100","doi-asserted-by":"publisher","first-page":"S334","DOI":"10.1016\/S0168-8278(12)60870-8","volume":"56","author":"R Liu","year":"2012","unstructured":"Liu R, Kong R, Mann P et al (2012) In vitro resistance analysis of HCV NS5A inhibitor MK-8742 demonstrates increased potency against clinical resistance variants ans higher resistance barrier. J Hepatol 56(2):S334\u2013S335","journal-title":"J Hepatol"},{"key":"12_CR101","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1128\/AAC.00677-09","volume":"54","author":"NJ Liverton","year":"2010","unstructured":"Liverton NJ, Carroll SS, Dimuzio J et al (2010) MK-7009, a potent and selective inhibitor of hepatitis C virus NS3\/4A protease. Antimicrob Agents Chemother 54:305\u2013311","journal-title":"Antimicrob Agents Chemother"},{"key":"12_CR102","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/S0092-8674(00)81350-1","volume":"87","author":"RA Love","year":"1996","unstructured":"Love RA, Parge HE, Wickersham JA et al (1996) The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site. Cell 87:331\u2013342","journal-title":"Cell"},{"key":"12_CR103","doi-asserted-by":"publisher","first-page":"4395","DOI":"10.1128\/JVI.02352-08","volume":"83","author":"RA Love","year":"2009","unstructured":"Love RA, Brodsky O, Hickey MJ et al (2009) Crystal structure of a novel dimeric form of NS5A domain I protein from hepatitis C virus. J Virol 83:4395\u20134403","journal-title":"J Virol"},{"key":"12_CR104","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1128\/AAC.49.5.2059-2069.2005","volume":"49","author":"SW Ludmerer","year":"2005","unstructured":"Ludmerer SW, Graham DJ, Boots E et al (2005) Replication fitness and NS5B drug sensitivity of diverse hepatitis C virus isolates characterized by using a transient replication assay. Antimicrob Agents Chemother 49:2059\u20132069","journal-title":"Antimicrob Agents Chemother"},{"key":"12_CR105","doi-asserted-by":"publisher","first-page":"12712","DOI":"10.1073\/pnas.0905966106","volume":"106","author":"P Luik","year":"2009","unstructured":"Luik P, Chew C, Aittoniemi J et al (2009) The 3-dimensional structure of a hepatitis C virus p7 ion channel by electron microscopy. Proc Natl Acad Sci USA 106:12712\u201312716","journal-title":"Proc Natl Acad Sci USA"},{"key":"12_CR106","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.antiviral.2010.02.312","volume":"86","author":"CA Luscombe","year":"2010","unstructured":"Luscombe CA, Huang Z, Murray MG et al (2010) A novel hepatitis C virus p7 ion channel inhibitor, BIT225, inhibits bovine viral diarrhea virus in vitro and shows synergism with recombinant interferon-alpha-2b and nucleoside analogues. Antiviral Res 86:144\u2013153","journal-title":"Antiviral Res"},{"key":"12_CR107","doi-asserted-by":"publisher","first-page":"29812","DOI":"10.1074\/jbc.M705274200","volume":"282","author":"H Ma","year":"2007","unstructured":"Ma H, Jiang WR, Robledo N et al (2007) Characterization of the metabolic activation of hepatitis C virus nucleoside inhibitor beta-D-2\u2032-deoxy-2\u2032-fluoro-2\u2032-C-methylcytidine (PSI-6130) and identification of a novel active 5\u2032-triphosphate species. J Biol Chem 282:29812\u201329820","journal-title":"J Biol Chem"},{"key":"12_CR108","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1099\/vir.0.80204-0","volume":"85","author":"A Macdonald","year":"2004","unstructured":"Macdonald A, Harris M (2004) Hepatitis C virus NS5A: tales of a promiscuous protein. J Gen Virol 85:2485\u20132502","journal-title":"J Gen Virol"},{"key":"12_CR109","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1016\/j.jhep.2010.08.040","volume":"54","author":"MP Manns","year":"2011","unstructured":"Manns MP, Bourliere M, Benhamou Y et al (2011) Potency, safety, and pharmacokinetics of the NS3\/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection. J Hepatol 54:1114\u20131122","journal-title":"J Hepatol"},{"key":"12_CR110","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.antiviral.2012.04.008","volume":"95","author":"MM May","year":"2012","unstructured":"May MM, Brohm D, Harrenga A et al (2012) Discovery of substituted N-phenylbenzenesulphonamides as a novel class of non-nucleoside hepatitis C virus polymerase inhibitors. Antiviral Res 95:182\u2013191","journal-title":"Antiviral Res"},{"key":"12_CR111","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1128\/AAC.01317-07","volume":"52","author":"MF McCown","year":"2008","unstructured":"McCown MF, Rajyaguru S, Le Pogam S et al (2008) The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors. Antimicrob Agents Chemother 52:1604\u20131612","journal-title":"Antimicrob Agents Chemother"},{"key":"12_CR112","doi-asserted-by":"publisher","first-page":"4850","DOI":"10.1016\/j.bmcl.2010.06.094","volume":"20","author":"C McGuigan","year":"2010","unstructured":"McGuigan C, Madela K, Aljarah M et al (2010) Design, synthesis and evaluation of a novel double pro-drug: INX-08189. A new clinical candidate for hepatitis C virus. Bioorg Med Chem Lett 20:4850\u20134854","journal-title":"Bioorg Med Chem Lett"},{"key":"12_CR113","doi-asserted-by":"publisher","first-page":"3670","DOI":"10.1128\/AAC.00308-12","volume":"56","author":"F McPhee","year":"2012","unstructured":"McPhee F, Friborg J, Levine S et al (2012a) Resistance analysis of the hepatitis C virus NS3 protease inhibitor asunaprevir. Antimicrob Agents Chemother 56:3670\u20133681","journal-title":"Antimicrob Agents Chemother"},{"key":"12_CR114","doi-asserted-by":"publisher","first-page":"5387","DOI":"10.1128\/AAC.01186-12","volume":"56","author":"F McPhee","year":"2012","unstructured":"McPhee F, Sheaffer AK, Friborg J et al (2012b) Preclinical profile and characterization of the hepatitis C virus NS3 protease inhibitor asunaprevir (BMS-650032). Antimicrob Agents Chemother 56:5387\u20135396","journal-title":"Antimicrob Agents Chemother"},{"key":"12_CR115","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.cld.2011.05.003","volume":"15","author":"FE Membreno","year":"2011","unstructured":"Membreno FE, Lawitz EJ (2011) The HCV NS5B nucleoside and non-nucleoside inhibitors. Clin Liver Dis 15:611\u2013626","journal-title":"Clin Liver Dis"},{"key":"12_CR116","doi-asserted-by":"publisher","first-page":"49164","DOI":"10.1074\/jbc.M305041200","volume":"278","author":"G Migliaccio","year":"2003","unstructured":"Migliaccio G, Tomassini JE, Carroll SS et al (2003) Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro. J Biol Chem 278:49164\u201349170","journal-title":"J Biol Chem"},{"key":"12_CR117","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1016\/j.jhep.2011.12.033","volume":"56","author":"C Moreno","year":"2012","unstructured":"Moreno C, Berg T, Tanwandee T et al (2012) Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2\u20136: TMC435-C202, a phase IIa, open-label study. J Hepatol 56:1247\u20131253","journal-title":"J Hepatol"},{"key":"12_CR118","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1128\/AAC.00400-06","volume":"51","author":"E Murakami","year":"2007","unstructured":"Murakami E, Bao H, Ramesh M et al (2007) Mechanism of activation of beta-D-2\u2032-deoxy-2\u2032-fluoro-2\u2032-c-methylcytidine and inhibition of hepatitis C virus NS5B RNA polymerase. Antimicrob Agents Chemother 51:503\u2013509","journal-title":"Antimicrob Agents Chemother"},{"key":"12_CR119","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1128\/AAC.01184-07","volume":"52","author":"E Murakami","year":"2008","unstructured":"Murakami E, Niu CR, Bao HY et al (2008) The mechanism of action of beta-D-2\u2032-deoxy-2\u2032-fluoro-2\u2032-C-methylcytidme involves a second metabolic pathway leading to beta-D-2\u2032-deoxy-2-fluoro-2\u2032-C-methyluridine 5\u2032-triphosphate, a potent inhibitor of the hepatitis C virus RNA-dependent RNA polymerase. Antimicrob Agents Chemother 52:458\u2013464","journal-title":"Antimicrob Agents Chemother"},{"key":"12_CR120","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1021\/jm1013105","volume":"54","author":"F Narjes","year":"2011","unstructured":"Narjes F, Crescenzi B, Ferrara M et al (2011) Discovery of (7R)-14-cyclohexyl-7-{[2-(dimethylamino)ethyl](methyl) amino}-7,8-dihydro-6H-indolo[1,2-e][1,5]benzoxazocine-11-carboxylic acid (MK-3281), a potent and orally bioavailable finger-loop inhibitor of the hepatitis C virus NS5B polymerase. J Med Chem 54:289\u2013301","journal-title":"J Med Chem"},{"key":"12_CR121","first-page":"1435A","volume":"54","author":"DR Nelson","year":"2011","unstructured":"Nelson DR, Gane EJ, Jacobson IM et al (2011) VX-222\/telaprevir in combination with peginterferon-alfa-2a and ribavirin in treatment-naive genotype 1 HCV patients treated for 12\u00a0weeks: zenith study, SVR12 interim analysis. Hepatology 54:1435A","journal-title":"Hepatology"},{"key":"12_CR122","doi-asserted-by":"publisher","first-page":"3525","DOI":"10.1128\/AAC.47.11.3525-3530.2003","volume":"47","author":"TT Nguyen","year":"2003","unstructured":"Nguyen TT, Gates AT, Gutshall LL et al (2003) Resistance profile of a hepatitis C virus RNA-dependent RNA polymerase benzothiadiazine inhibitor. Antimicrob Agents Chemother 47:3525\u20133530","journal-title":"Antimicrob Agents Chemother"},{"key":"12_CR123","doi-asserted-by":"publisher","first-page":"3944","DOI":"10.1128\/AAC.48.10.3944-3953.2004","volume":"48","author":"DB Olsen","year":"2004","unstructured":"Olsen DB, Eldrup AB, Bartholomew L et al (2004) A 7-deaza-adenosine analog is a potent and selective inhibitor of hepatitis C virus replication with excellent pharmacokinetic properties. Antimicrob Agents Chemother 48:3944\u20133953","journal-title":"Antimicrob Agents Chemother"},{"key":"12_CR124","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1128\/AAC.05854-11","volume":"56","author":"C Pasquinelli","year":"2012","unstructured":"Pasquinelli C, McPhee F, Eley T et al (2012) Single- and multiple-ascending-dose studies of the NS3 protease inhibitor asunaprevir in subjects with or without chronic hepatitis C. Antimicrob Agents Chemother 56:1838\u20131844","journal-title":"Antimicrob Agents Chemother"},{"key":"12_CR125","doi-asserted-by":"publisher","first-page":"6909","DOI":"10.1128\/JVI.01543-06","volume":"81","author":"F Pauwels","year":"2007","unstructured":"Pauwels F, Mostmans W, Quirynen LMM et al (2007) Binding-site identification and genotypic profiling of hepatitis C virus polymerase inhibitors. J Virol 81:6909\u20136919","journal-title":"J Virol"},{"key":"12_CR126","doi-asserted-by":"publisher","first-page":"411","DOI":"10.3851\/IMP2088","volume":"17","author":"JM Pawlotsky","year":"2012","unstructured":"Pawlotsky JM, Najera I, Jacobson I (2012) Resistance to mericitabine, a nucleoside analogue inhibitor of HCV RNA-dependent RNA polymerase. Antivir Ther 17:411\u2013423","journal-title":"Antivir Ther"},{"key":"12_CR127","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/S1665-2681(19)31486-3","volume":"11","author":"MG Pessoa","year":"2012","unstructured":"Pessoa MG, Cheinquer H, Almeida PR et al (2012) Re-treatment of previous non-responders and relapsers to interferon plus ribavirin with peginterferon alfa-2a (40KD), ribavirin\u00a0\u00b1\u00a0amantadine in patients with chronic hepatitis C: randomized multicentre clinical trial. Ann Hepatol 11:52\u201361","journal-title":"Ann Hepatol"},{"key":"12_CR128","doi-asserted-by":"publisher","first-page":"6614","DOI":"10.1021\/jm0603623","volume":"49","author":"C Pierra","year":"2006","unstructured":"Pierra C, Amador A, Benzaria S et al (2006) Synthesis and pharmacokinetics of valopicitabine (NM283), an efficient prodrug of the potent anti-HCV agent 2\u2032-C-methylcytidine. J Med Chem 49:6614\u20136620","journal-title":"J Med Chem"},{"key":"12_CR129","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S1473-3099(12)70138-X","volume":"12","author":"S Pol","year":"2012","unstructured":"Pol S, Ghalib RH, Rustgi VK et al (2012) Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial. Lancet Infect Dis 12:671\u2013677","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"12_CR130","doi-asserted-by":"publisher","first-page":"S549","DOI":"10.1016\/S0168-8278(12)61410-X","volume":"56","author":"F Poordad","year":"2012","unstructured":"Poordad F, Lawitz E, Kowdley KV et al (2012a) 12\u00a0weeks interferon-free regimen of ABT-450\/R\u00a0+\u00a0ABT-333\u00a0+\u00a0ribavirin achieved SVR12 in more than 90\u00a0% of treatment-naive HCV genotype-1-infected subjects and 47\u00a0% of previous non-responders. J Hepatol 56(2):S549\u2013S550","journal-title":"J Hepatol"},{"key":"12_CR131","doi-asserted-by":"publisher","first-page":"S549","DOI":"10.1016\/S0168-8278(12)61410-X","volume":"56","author":"F Poordad","year":"2012","unstructured":"Poordad F, Lawitz E, Kowdley KV et al (2012b) 12\u00a0weeks interferon-free regimen of ABT-450\/R\u00a0+\u00a0ABT-333\u00a0+\u00a0ribavirin achieved svr12 in more than 90\u00a0% of treatment-naive HCV genotype-1-infected subjects and 47\u00a0% of previous non-responders. J Hepatol 56:S549\u2013S550","journal-title":"J Hepatol"},{"key":"12_CR132","doi-asserted-by":"publisher","first-page":"2502","DOI":"10.1099\/vir.0.034801-0","volume":"92","author":"D Qiu","year":"2011","unstructured":"Qiu D, Lemm JA, O\u2019Boyle DR 2nd et al (2011) The effects of NS5A inhibitors on NS5A phosphorylation, polyprotein processing and localization. J Gen Virol 92:2502\u20132511","journal-title":"J Gen Virol"},{"key":"12_CR133","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.antiviral.2011.01.009","volume":"90","author":"R Rai","year":"2011","unstructured":"Rai R, Deval J (2011) New opportunities in anti-hepatitis C virus drug discovery: targeting NS4B. Antiviral Res 90:93\u2013101","journal-title":"Antiviral Res"},{"key":"12_CR134","doi-asserted-by":"publisher","first-page":"457","DOI":"10.2165\/11599700-000000000-00000","volume":"51","author":"MB Reddy","year":"2012","unstructured":"Reddy MB, Chen Y, Haznedar JO et al (2012) Impact of low-dose ritonavir on danoprevir pharmacokinetics: results of computer-based simulations and a clinical drug-drug interaction study. Clin Pharmacokinet 51:457\u2013465","journal-title":"Clin Pharmacokinet"},{"key":"12_CR135","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1053\/j.gastro.2009.10.033","volume":"138","author":"HW Reesink","year":"2010","unstructured":"Reesink HW, Fanning GC, Farha KA et al (2010) Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients. Gastroenterology 138:913\u2013921","journal-title":"Gastroenterology"},{"key":"12_CR136","unstructured":"Reghellin V, Fenu S, Bianco A et al (2012) HCV NS5A inhibitor BMS-790052 exerts its antiviral effects by reducing phosphatidylinositol 4-phosphate levels in the virus-induced membranous web. In: Abstracts LB-9 of the 19th international symposium on hepatitis C virus and related viruses, Venice, Italy, 5\u20139 Octo 2012"},{"key":"12_CR137","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.chom.2010.12.002","volume":"9","author":"S Reiss","year":"2011","unstructured":"Reiss S, Rebhan I, Backes P et al (2011) Recruitment and activation of a lipid kinase by hepatitis C virus NS5A is essential for integrity of the membranous replication compartment. Cell Host Microbe 9:32\u201345","journal-title":"Cell Host Microbe"},{"key":"12_CR138","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1016\/S0168-8278(10)60033-5","volume":"52","author":"M Rodriguez-Torres","year":"2010","unstructured":"Rodriguez-Torres M, Lawitz E, Conway B et al (2010) Safety and antiviral activity of the HCV non-nucleoside polymerase inhibitor VX-222 in treatment-naive genotype 1 HCV-infected patients. J Hepatol 52:S14","journal-title":"J Hepatol"},{"key":"12_CR139","first-page":"535A","volume":"54","author":"M Rodriguez-Torres","year":"2011","unstructured":"Rodriguez-Torres M, Lawitz E, Hazan L et al (2011) Antiviral activity and safety of INX-08189, a nucleotide polymerase inhibitor, following 7\u00a0days of oral therapy in naive genotype-1 chronic HCV patients. Hepatology 54:535A","journal-title":"Hepatology"},{"key":"12_CR140","doi-asserted-by":"publisher","first-page":"e1002832","DOI":"10.1371\/journal.ppat.1002832","volume":"8","author":"KP Romano","year":"2012","unstructured":"Romano KP, Ali A, Aydin C et al (2012) The molecular basis of drug resistance against hepatitis C virus NS3\/4A protease inhibitors. Plos Pathog 8:e1002832","journal-title":"Plos Pathog"},{"key":"12_CR141","doi-asserted-by":"publisher","first-page":"11646","DOI":"10.1073\/pnas.1834545100","volume":"100","author":"A Sakai","year":"2003","unstructured":"Sakai A, St Claire MS, Faulk K et al (2003) The p7 polypeptide of hepatitis C virus is critical for infectivity and contains functionally important genotype-specific sequences. Proc Natl Acad Sci USA 100:11646\u201311651","journal-title":"Proc Natl Acad Sci USA"},{"key":"12_CR142","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1053\/j.gastro.2009.11.055","volume":"138","author":"C Sarrazin","year":"2010","unstructured":"Sarrazin C, Zeuzem S (2010) Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 138:447\u2013462","journal-title":"Gastroenterology"},{"key":"12_CR143","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1053\/j.gastro.2007.02.037","volume":"132","author":"C Sarrazin","year":"2007","unstructured":"Sarrazin C, Kieffer TL, Bartels D et al (2007) Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 132:1767\u20131777","journal-title":"Gastroenterology"},{"issue":"1","key":"12_CR144","doi-asserted-by":"publisher","first-page":"S88","DOI":"10.1016\/S0168-8278(12)60010-5","volume":"56","author":"C Sarrazin","year":"2012","unstructured":"Sarrazin C, Hezode C, Zeuzem S, Pawlotsky JM (2012) Antiviral strategies in hepatitis C virus infection. J Hepatol 56(1):S88\u2013S100","journal-title":"J Hepatol"},{"issue":"1340\u20131350","key":"12_CR145","first-page":"e1341","volume":"142","author":"EA Schaefer","year":"2012","unstructured":"Schaefer EA, Chung RT (2012) Anti-hepatitis C virus drugs in development. Gastroenterology 142(1340\u20131350):e1341","journal-title":"Gastroenterology"},{"key":"12_CR146","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S0006-291X(67)80055-X","volume":"27","author":"I Schechter","year":"1967","unstructured":"Schechter I, Berger A (1967) On the size of the active site in proteases. I Papain Biochem Biophys Res Commun 27:157\u2013162","journal-title":"I Papain Biochem Biophys Res Commun"},{"key":"12_CR147","doi-asserted-by":"publisher","first-page":"4432","DOI":"10.1128\/AAC.00699-08","volume":"52","author":"SD Seiwert","year":"2008","unstructured":"Seiwert SD, Andrews SW, Jiang Y et al (2008) Preclinical characteristics of the hepatitis C virus NS3\/4A protease inhibitor ITMN-191 (R7227). Antimicrob Agents Chemother 52:4432\u20134441","journal-title":"Antimicrob Agents Chemother"},{"key":"12_CR148","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.1016\/j.bmcl.2012.01.017","volume":"22","author":"XC Sheng","year":"2012","unstructured":"Sheng XC, Appleby T, Butler T et al (2012a) Discovery of GS-9451: an acid inhibitor of the hepatitis C virus NS3\/4A protease. Bioorg Med Chem Lett 22:2629\u20132634","journal-title":"Bioorg Med Chem Lett"},{"key":"12_CR149","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1016\/j.bmcl.2011.12.038","volume":"22","author":"XC Sheng","year":"2012","unstructured":"Sheng XC, Casarez A, Cai R et al (2012b) Discovery of GS-9256: a novel phosphinic acid derived inhibitor of the hepatitis C virus NS3\/4A protease with potent clinical activity. Bioorg Med Chem Lett 22:1394\u20131396","journal-title":"Bioorg Med Chem Lett"},{"key":"12_CR150","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/S1473-3099(05)70216-4","volume":"5","author":"CW Shepard","year":"2005","unstructured":"Shepard CW, Finelli L, Alter MJ (2005) Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 5:558\u2013567","journal-title":"Lancet Infect Dis"},{"key":"12_CR151","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1128\/AAC.01599-08","volume":"53","author":"ST Shi","year":"2009","unstructured":"Shi ST, Herlihy KJ, Graham JP et al (2009) Preclinical characterization of PF-00868554, a potent nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase. Antimicrob Agents Chemother 53:2544\u20132552","journal-title":"Antimicrob Agents Chemother"},{"key":"12_CR152","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1021\/jm061207r","volume":"50","author":"MJ Slater","year":"2007","unstructured":"Slater MJ, Amphlett EM, Andrews DM et al (2007) Optimization of novel acyl pyrrolidine inhibitors of hepatitis C virus RNA-dependent RNA polymerase leading to a development candidate. J Med Chem 50:897\u2013900","journal-title":"J Med Chem"},{"key":"12_CR153","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1023\/A:1018857314351","volume":"42","author":"JP Smith","year":"1997","unstructured":"Smith JP (1997) Treatment of chronic hepatitis C with amantadine. Dig Dis Sci 42:1681\u20131687","journal-title":"Dig Dis Sci"},{"key":"12_CR154","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1371\/journal.ppat.0030103","volume":"3","author":"E Steinmann","year":"2007","unstructured":"Steinmann E, Penin F, Kallis S et al (2007a) Hepatitis C virus p7 protein is crucial for assembly and release of infectious virions. Plos Pathog 3:962\u2013971","journal-title":"Plos Pathog"},{"key":"12_CR155","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1002\/hep.21686","volume":"46","author":"E Steinmann","year":"2007","unstructured":"Steinmann E, Whitfield T, Kallis S et al (2007b) Antiviral effects of amantadine and iminosugar derivatives against hepatitis C virus. Hepatology 46:330\u2013338","journal-title":"Hepatology"},{"key":"12_CR156","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1177\/095632020601700203","volume":"17","author":"LJ Stuyver","year":"2006","unstructured":"Stuyver LJ, McBrayer TR, Tharnish PM et al (2006) Inhibition of hepatitis C replicon RNA synthesis by beta-D-2\u2032-deoxy-2\u2032-fluoro-2\u2032-C-methylcytidine: a specific inhibitor of hepatitis C virus replication. Antivir Chem Chemother 17:79\u201387","journal-title":"Antivir Chem Chemother"},{"key":"12_CR157","first-page":"S560","volume":"56","author":"M Sulkowski","year":"2012","unstructured":"Sulkowski M, Rodriguez-Torres M, Lawitz E et al (2012a) High sustained virologic response rate in treatment-na\u00efve HCV genotype 1a and 1b patients treated for 12\u00a0weeks with an interferon-free all-oral quad regimen: interim results. J Hepatol 56:S560","journal-title":"J Hepatol"},{"key":"12_CR158","doi-asserted-by":"crossref","unstructured":"Sulkowski MS, Gardiner DF, Rodriguez-Torres M et al (2012b) High rate of sustained virologic response with the all-oral combination of daclatasvir (NS5A inhibitor) plus sofosbuvir (nucleotide NS5B inhibitor), with or without ribavirin, in treatment-na\u00efve patients chronically infected with HCV genotype 1, 2, or 3. In: Abstracts LB-2 of the 63rd annual meeting of the american association for the study of liver diseases, Boston, Massachusetts, 9\u201313 Nov 2012","DOI":"10.1016\/S0168-8278(12)61433-0"},{"key":"12_CR159","doi-asserted-by":"publisher","first-page":"4161","DOI":"10.1128\/AAC.00324-12","volume":"56","author":"V Summa","year":"2012","unstructured":"Summa V, Ludmerer SW, McCauley JA et al (2012) MK-5172, a selective inhibitor of hepatitis C virus NS3\/4a protease with broad activity across genotypes and resistant variants. Antimicrob Agents Chemother 56:4161\u20134167","journal-title":"Antimicrob Agents Chemother"},{"key":"12_CR160","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1002\/hep.23192","volume":"50","author":"S Susser","year":"2009","unstructured":"Susser S, Welsch C, Wang Y et al (2009) Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology 50:1709\u20131718","journal-title":"Hepatology"},{"issue":"1","key":"12_CR161","first-page":"64","volume":"7","author":"T Tanwandee","year":"2011","unstructured":"Tanwandee T, Luscombe CA, Ewart G et al (2011) Antiviral activity and tolerability of BIT225 plus pegylated interferon alpha 2a or 2b and weight-based ribavirin for 28\u00a0days in HCV treatment-na\u00efve monoinfected patients. Glob Antiviral J 7(1):64 HEP DART 2011","journal-title":"Glob Antiviral J"},{"key":"12_CR162","doi-asserted-by":"publisher","first-page":"6353","DOI":"10.1128\/JVI.00215-11","volume":"85","author":"P Targett-Adams","year":"2011","unstructured":"Targett-Adams P, Graham EJ, Middleton J et al (2011) Small molecules targeting hepatitis C virus-encoded NS5A cause subcellular redistribution of their target: insights into compound modes of action. J Virol 85:6353\u20136368","journal-title":"J Virol"},{"key":"12_CR163","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1038\/nature03580","volume":"435","author":"TL Tellinghuisen","year":"2005","unstructured":"Tellinghuisen TL, Marcotrigiano J, Rice CM (2005) Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase. Nature 435:374\u2013379","journal-title":"Nature"},{"key":"12_CR164","doi-asserted-by":"publisher","first-page":"S37","DOI":"10.1016\/S0168-8278(09)60092-1","volume":"50","author":"P Thompson","year":"2009","unstructured":"Thompson P, Patel R, Steffy K, Appleman J (2009) Preclinical studies of ANA598 combined with other Anti-HCV agents demonstrate potential of combination treatment. J Hepatol 50:S37","journal-title":"J Hepatol"},{"key":"12_CR165","doi-asserted-by":"publisher","first-page":"4017","DOI":"10.1128\/jvi.67.7.4017-4026.1993","volume":"67","author":"L Tomei","year":"1993","unstructured":"Tomei L, Failla C, Santolini E et al (1993) NS3 is a serine protease required for processing of hepatitis C virus polyprotein. J Virol 67:4017\u20134026","journal-title":"J Virol"},{"key":"12_CR166","doi-asserted-by":"publisher","first-page":"13225","DOI":"10.1128\/JVI.77.24.13225-13231.2003","volume":"77","author":"L Tomei","year":"2003","unstructured":"Tomei L, Altamura S, Bartholomew L et al (2003) Mechanism of action and antiviral activity of benzimidazole-based allosteric inhibitors of the hepatitis C virus RNA-dependent RNA polymerase. J Virol 77:13225\u201313231","journal-title":"J Virol"},{"key":"12_CR167","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1128\/JVI.78.2.938-946.2004","volume":"78","author":"L Tomei","year":"2004","unstructured":"Tomei L, Altamura S, Bartholomew L et al (2004) Characterization of the inhibition of hepatitis C virus RNA replication by nonnucleosides. J Virol 78:938\u2013946","journal-title":"J Virol"},{"key":"12_CR168","doi-asserted-by":"publisher","first-page":"3669","DOI":"10.1128\/JVI.77.6.3669-3679.2003","volume":"77","author":"C Trozzi","year":"2003","unstructured":"Trozzi C, Bartholomew L, Ceccacci A et al (2003) In vitro selection and characterization of hepatitis C virus serine protease variants resistant to an active-site peptide inhibitor. J Virol 77:3669\u20133679","journal-title":"J Virol"},{"key":"12_CR169","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1128\/AAC.01335-10","volume":"55","author":"JH Vernachio","year":"2011","unstructured":"Vernachio JH, Bleiman B, Bryant KD et al (2011) INX-08189, a phosphoramidate prodrug of 6-O-methyl-2\u2032-C-methyl guanosine, is a potent inhibitor of hepatitis C virus replication with excellent pharmacokinetic and pharmacodynamic properties. Antimicrob Agents Chemother 55:1843\u20131851","journal-title":"Antimicrob Agents Chemother"},{"key":"12_CR170","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1002\/hep.22483","volume":"48","author":"M von Wagner","year":"2008","unstructured":"von Wagner M, Hofmann WP, Teuber G et al (2008) Placebo-controlled trial of 400\u00a0mg amantadine combined with peginterferon alfa-2a and ribavirin for 48\u00a0weeks in chronic hepatitis C virus-1 infection. Hepatology 48:1404\u20131411","journal-title":"Hepatology"},{"key":"12_CR171","unstructured":"Wagaw S, Ravn M, Engstrom K et al (2009) Process for making macrocyclic oximyl hepatitis C protease inhibitors. WO\/2009\/073780"},{"key":"12_CR172","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1002\/hep.24342","volume":"54","author":"F Wagner","year":"2011","unstructured":"Wagner F, Thompson R, Kantaridis C et al (2011) Antiviral activity of the hepatitis C virus polymerase inhibitor filibuvir in genotype 1-infected patients. Hepatology 54:50\u201359","journal-title":"Hepatology"},{"key":"12_CR173","doi-asserted-by":"publisher","first-page":"9489","DOI":"10.1074\/jbc.M209397200","volume":"278","author":"M Wang","year":"2003","unstructured":"Wang M, Ng KK, Cherney MM et al (2003) Non-nucleoside analogue inhibitors bind to an allosteric site on HCV NS5B polymerase. Crystal structures and mechanism of inhibition. J Biol Chem 278:9489\u20139495","journal-title":"J Biol Chem"},{"key":"12_CR174","doi-asserted-by":"publisher","first-page":"4611","DOI":"10.1128\/AAC.00787-10","volume":"54","author":"PW White","year":"2010","unstructured":"White PW, Llinas-Brunet M, Amad M et al (2010) Preclinical characterization of BI 201335, a C-terminal carboxylic acid inhibitor of the hepatitis C virus NS3-NS4A protease. Antimicrob Agents Chemother 54:4611\u20134618","journal-title":"Antimicrob Agents Chemother"},{"key":"12_CR175","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1002\/pro.5560070402","volume":"7","author":"Y Yan","year":"1998","unstructured":"Yan Y, Li Y, Munshi S et al (1998) Complex of NS3 protease and NS4A peptide of BK strain hepatitis C virus: a 2.2 A resolution structure in a hexagonal crystal form. Protein Sci 7:837\u2013847","journal-title":"Protein Sci"},{"issue":"2","key":"12_CR176","doi-asserted-by":"publisher","first-page":"S330","DOI":"10.1016\/S0168-8278(12)60857-5","volume":"56","author":"G Yang","year":"2012","unstructured":"Yang G, Wiles J, Patel D et al (2012) Preclinical characteristics of of ACH-3102: a novel HCV NS5A inhibitor with imporved potency against genotype-1a virus and variants resistant to 1st generation of NS5A inhibitors. J Hepatol 56(2):S330","journal-title":"J Hepatol"},{"key":"12_CR177","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1128\/AAC.05438-11","volume":"56","author":"G Yi","year":"2012","unstructured":"Yi G, Deval J, Fan B et al (2012) Biochemical study of the comparative inhibition of hepatitis C virus RNA polymerase by VX-222 and filibuvir. Antimicrob Agents Chemother 56:830\u2013837","journal-title":"Antimicrob Agents Chemother"},{"key":"12_CR178","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1002\/hep.24744","volume":"55","author":"S Zeuzem","year":"2012","unstructured":"Zeuzem S, Buggisch P, Agarwal K et al (2012a) The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C. Hepatology 55:749\u2013758","journal-title":"Hepatology"},{"key":"12_CR179","unstructured":"Zeuzem S, Soriano A, Asselah T et al (2012b) Interferon (IFN)-free combination treatment with the HCV NS3\/4A protease inhibitor BI 201335 and the non-nucleoside NS5B inhibitor BI 207127\u00a0\u00b1\u00a0ribavirin (R): final results of SOUND-C2 and predictors of response. In: Abstracts 232 of the 63rd annual meeting of the american association for the study of liver diseases, Boston, Massachusetts, 9\u201313 Nov 2012"},{"key":"12_CR180","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1128\/AAC.01101-10","volume":"55","author":"XJ Zhou","year":"2011","unstructured":"Zhou XJ, Pietropaolo K, Chen J et al (2011) Safety and pharmacokinetics of IDX184, a liver-targeted nucleotide polymerase inhibitor of hepatitis C virus, in healthy subjects. Antimicrob Agents Chemother 55:76\u201381","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Current Topics in Microbiology and Immunology","Hepatitis C Virus: From Molecular Virology to Antiviral Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-642-27340-7_12","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T22:06:33Z","timestamp":1715033193000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-642-27340-7_12"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013]]},"ISBN":["9783642273391","9783642273407"],"references-count":181,"URL":"https:\/\/doi.org\/10.1007\/978-3-642-27340-7_12","relation":{},"ISSN":["0070-217X","2196-9965"],"issn-type":[{"value":"0070-217X","type":"print"},{"value":"2196-9965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013]]}}}